Patents matching “antagonist”

US 10370449

Methods for treating skin infection by administering an IL-4R antagonist

REGENERON PHARMACEUTICALS, INC. · Granted Aug 6, 2019 · Expires Aug 1, 2039

US 10358433

Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity

Theravance Respiratory Company, LLC · Granted Jul 23, 2019 · Expires Jul 18, 2039

US 10343995

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance Biopharma R&D IP, LLC · Granted Jul 9, 2019 · Expires Jul 4, 2039

US 10336769

Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

Neurocrine Biosciences, Inc. · Granted Jul 2, 2019 · Expires Jun 27, 2039

US 10329343

Methods for treating headache using antagonist antibodies directed against calcitonin gene-related peptide

TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Jun 25, 2019 · Expires Jun 20, 2039

US 10322161

EPHA4 cyclic peptide antagonists for neuroprotection and neural repair

SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Jun 18, 2019 · Expires Jun 13, 2039

US 10316073

FCRN antagonists and methods of use

The Board of Regents of the University of Texas System · Granted Jun 11, 2019 · Expires Jun 6, 2039

US 10314904

Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist

REGENERON PHARMACEUTICALS, INC. · Granted Jun 11, 2019 · Expires Jun 6, 2039

US 10301371

Cyclic monomer and dimer peptides having integrin antagonist activity

Protagonist Therapeutics, Inc. · Granted May 28, 2019 · Expires May 23, 2039

US 10300074

Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy

SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted May 28, 2019 · Expires May 23, 2039

US 10300072

Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities

Almirall, S.A. · Granted May 28, 2019 · Expires May 23, 2039

US 10258582

Nicotinic receptor non-competitive antagonists

Catalyst Biosciences, Inc. · Granted Apr 16, 2019 · Expires Apr 11, 2039

US 10238659

Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

Corcept Therapeutics Incorporated · Granted Mar 26, 2019 · Expires Mar 21, 2039

US 10239870

Dopamine D3 receptor antagonists

Indivior UK Limited · Granted Mar 26, 2019 · Expires Mar 21, 2039

US 10137193

Methods for treating or preventing asthma by administering an IL-4R antagonist

REGENERON PHARMACEUTICALS, INC. · Granted Nov 27, 2018 · Expires Nov 22, 2038

US 10130681

Use of a VEGF antagonist to treat angiogenic eye disorders

REGENERON PHARMACEUTICALS, INC. · Granted Nov 20, 2018 · Expires Nov 15, 2038

US 10125145

5-HT3 receptor antagonists

Takeda Pharmaceutical Company Limited · Granted Nov 13, 2018 · Expires Nov 8, 2038

US 10105366

Selective calcium channel antagonists

Northwestern University · Granted Oct 23, 2018 · Expires Oct 18, 2038

US 10106616

Antagonist antibodies to human prolactin receptor (PRLR)

REGENERON PHARMACEUTICALS, INC. · Granted Oct 23, 2018 · Expires Oct 18, 2038

US 10106503

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance Biopharma R&D IP, LLC · Granted Oct 23, 2018 · Expires Oct 18, 2038

US 10105316

Inhalation compositions comprising muscarinic receptor antagonist

ARVEN ILAC SANAYI VE TICARET A.S. · Granted Oct 23, 2018 · Expires Oct 18, 2038

US 10100018

Amide derivatives as lysophosphatidic acid receptor antagonists

Takeda Pharmaceutical Company Limited · Granted Oct 16, 2018 · Expires Oct 11, 2038

US 10081626

8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists

Theravance Biopharma R&D IP, LLC · Granted Sep 25, 2018 · Expires Sep 20, 2038

US 10066017

Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist

REGENERON PHARMACEUTICALS, INC. · Granted Sep 4, 2018 · Expires Aug 30, 2038